# Second-generation Sequencing Guides the Treatment of Severe Pneumonia

> **NCT03884881** · NA · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 400 (actual)

## Conditions studied

- Pneumonia
- Metagenomic Next Generation Sequencing

## Interventions

- **DIAGNOSTIC_TEST:** metagenomic next generation sequencing
- **DIAGNOSTIC_TEST:** Conventional pathogen detection
- **DRUG:** Meropenem，Imipenem，Caspofene，Osstat

## Key facts

- **NCT ID:** NCT03884881
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884881, "Second-generation Sequencing Guides the Treatment of Severe Pneumonia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03884881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*